Research programme: tendon injury therapeutics - BioibericaAlternative Names: BIS-033
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bioiberica
- Class Polysaccharides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Tendon injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Tendon injuries in Spain
- 21 Oct 2009 Preclinical trials in Tendon injuries in Spain (unspecified route)